tomorrow. <\/em><\/p>\nJean-Luc Eisel\u00e9, Chief Executive Officer, World Heart Federation, said \u201cThe morbidity and mortality rates of HF remain high globally, despite the significant advances in treatment and prevention. WHF\u2019s HF Roadmap, created with an overall objective of reducing the global burden of HF, and our partnership with AstraZeneca is helping us improve the health of people living with HF.\u201d<\/p>\n
Additional partnership efforts include AstraZeneca\u2019s support of the WHF\u2019s Use Heart to Fight COVID-19<\/em> campaign, launched earlier this year to address the vulnerability of people with HF and other CV, renal and metabolic (CVRM) conditions during the pandemic. AstraZeneca and the WHF will also work closely on policy initiatives which will elevate HF as a political priority, and aim to change the current treatment landscape.<\/p>\nHeart Failure <\/strong><\/p>\nHF is a life-threatening disease in which the heart cannot pump enough blood around the body.2<\/sup>\u00a0It affects approximately 64 million people worldwide,\u00a0and is a chronic and degenerative disease where approximately half of patients will die within five years of diagnosis.3-5<\/sup>\u00a0HF remains as fatal as some of the most common cancers in both men (prostate and bladder cancers) and women (breast cancers).6<\/sup>\u00a0It is the leading cause of hospitalisation for those over the age of 65 and represents a significant clinical and economic burden.7<\/sup><\/p>\nWorld Heart Federation <\/strong><\/p>\nThe World Heart Federation (WHF) is the world\u2019s leading voice in cardiovascular health, with more than 200 member organisations across 100 countries. The WHF mission is to help people across the world lead longer and better lives through prevention and control of heart disease and stroke, with a focus on equal access to heart health care.<\/p>\n
AstraZeneca in CVRM\u00a0<\/strong><\/p>\nCardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca\u2019s three therapy areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling comorbidities. The Company\u2019s ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of\u00a0patients worldwide.<\/p>\n
References<\/strong><\/p>\n\nAstraZeneca PLP. Data on File. ID: REF \u2013 74964. March 2020<\/li>\n Mayo Clinic. Heart failure; 2017 [cited 2020 Aug 04]. Available from: URL: https:\/\/www.mayoclinic.org\/diseases-conditions\/heart-failure\/symptoms-causes\/syc-20373142<\/a>.<\/li>\nVos T et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet<\/em> 2017; 390(10100):1211\u201359.<\/li>\nBhuiyan T, Maurer MS. Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma. Curr Cardiovasc Risk Rep<\/em> 2011; 5(5):440\u20139.<\/li>\nMozaffarian D et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation<\/em> 2016; 133(4):e38-360.<\/li>\nMamas MA et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail<\/em> 2017; 19(9):1095\u2013104.<\/li>\nAzad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol<\/em> 2014; 11(4):329\u201337.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"New initiatives will raise public awareness of the burden of heart failure to drive a transformation in HF prevention, diagnosis, and treatment. 24 AUGUST 2020 AstraZeneca today announced a new partnership with the leading voice in cardiovascular (CV) health, the World Heart Federation (WHF), to drive global action to prevent, control and reduce the burden […]<\/p>\n","protected":false},"featured_media":3086,"template":"","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"event":[],"project-campaign":[],"topic":[166],"class_list":["post-3085","news","type-news","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n
AstraZeneca and the World Heart Federation partner to tackle gaps<\/title>\n \n \n \n \n \n \n \n \n \n \n\t \n\t \n\t \n \n \n\t \n